Why is the chief executive officer leaving Imugene (ASX:IMU)?

Leslie Chong stepped down as chief executive officer of Imugene (ASX:IMU) for personal reasons after serving in the position for nearly 11 years. She will remain available to assist with the transition while the board searches for new leadership.

What was the immediate share price reaction for Imugene (ASX:IMU)?

Following the executive resignation, the Imugene (ASX:IMU) share price remained unchanged at $0.09. The market update coincided with a recently completed $11.1 million capital raise.

How is Imugene (ASX:IMU) handling the executive transition process?

The board of Imugene (ASX:IMU) initiated an immediate search process to recruit a new chief executive officer. Outgoing leader Leslie Chong agreed to support the business during the transition period to ensure operational continuity.

What does this leadership change mean for the clinical pipeline at Imugene (ASX:IMU)?

Imugene (ASX:IMU) stated that it will continue the clinical development of its lead azer-cel cell therapy program for cancer treatments. The company expects further data readouts and milestone events from the trial program to move forward as planned.

What is the global operational reach of Imugene (ASX:IMU)?

Imugene (ASX:IMU) operates as a clinical-stage immuno-oncology business running clinical trials across multiple global research sites. Its broader strategy centers on advancing a portfolio of novel cancer therapies and cell treatment programs.

Image for illustrative purposes only. Not a real photo.

Imugene CEO steps down after 11 years

Written by Heidi Cuthbert Published Jul 27, 2026, 3:28 AM

· Leslie Chong has stepped down as CEO of Imugene after nearly 11 years.

· The company share price traded unchanged at $0.09 following the executive departure announcement.

· Imugene has initiated an immediate search process to select a new CEO.

Imugene (ASX:IMU) CEO Leslie Chong has stepped down after nearly 11 years of service.

The executive departure follows an $11.1 million capital raise completed earlier in July.

"I do so with confidence in Imugene's future," said Imugene CEO Leslie Chong.

The board started an immediate search process for new leadership while Chong assisted during the transition.

Following the announcement, the Imugene share price was unchanged at $0.09.

The company continues clinical development of its lead Azer-cel cell therapy programme for cancer treatments.

Imugene previously expanded its immuno-oncology portfolio through clinical trials across multiple global research sites.

Imugene CEO steps down after 11 years

Frequently asked questions

Assets related to this article